SCHEMBL23142017

SCHEMBL23142017

CSc1ncc(CO)c(NC(C)C(C)C)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.46
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SYK P43405 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CDK5 Q00535 1/20 0.32
DYRK1A Q13627 1/20 0.32
CDK5R1 Q15078 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
THRB P10828 1/20 0.32
ACACB O00763 1/20 0.31
LMNA P02545 1/20 0.31
FOS P01100 1/20 0.31
JUN P05412 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23142016 1.00 HTT (0.46) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL1521541 0.88 HTT (0.48) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL23142092 0.86 HTT (0.45) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL23142093 0.86 HTT (0.45) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL22860104 0.84 HTT (0.46) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL22860671 0.82 HTT (0.46) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL23141916 0.82 HTT (0.44) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL23141915 0.82 HTT (0.44) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL24670097 0.80 HTT (0.42) HTTALDH1A1MAPTSMN1; SMN2SYK
SCHEMBL1521589 0.80 HTT (0.51) HTTALDH1A1MAPTSMN1; SMN2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 US disclosed
EP-3797107-B1 HETEROCONDENSED PYRIDONE COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2022-08-10 EP disclosed
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-07-08 US disclosed
EP-3797107-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2021-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors IDH1, IDH2, IDH3A HTT 508/4885ALDH1A1 305/4885MAPT 3614/4885
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS IDH1, IDH2, IDH3A HTT 508/4885ALDH1A1 305/4885MAPT 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.